One-Year Real-World Study on Comparison among Different Continuous Subcutaneous Insulin Infusion Devices for the Management of Pediatric Patients with Type 1 Diabetes
The Supremacy of Hybrid Closed-Loop Systems
Bibliographic Data
| ID | 15470337 |
|---|---|
| Authors | Bruno Bombaci (0000-0001-8664-1025, University of Messina), Stefano Passanisi (0000-0002-4369-7798, University of Messina, corresponding author), Angela Alibrandi (0000-0001-6695-151X, University of Messina), Giulia D’Arrigo (0000-0002-1113-2266, University of Messina), Serena Patroniti (0000-0001-9903-2229, University of Messina), Simona Averna (University of Messina), Giuseppina Salzano (0000-0003-2180-4510, University of Messina), Fortunato Lombardo (0000-0002-7081-5884, University of Messina) |
| Year | 2022 |
| Volume | 19 |
| Issue | 16 |
| Pages | 10293-10293 |
| Publication date | 2022-08-18 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | International Journal of Environmental Research and Public Health (JOURNAL) |
| Journal identifiers | ISSN: 1661-7827 • E-ISSN: 1660-4601 |
| Publisher | Multidisciplinary Digital Publishing Institute (PUBLISHER • CH) |
| DOI | 10.3390/ijerph191610293 |
| PMID | 36011925 |
| OpenAlex | W4293679034 |
| Language | EN |
| References cited | 40 |
Since their advent in daily clinical practice, continuous subcutaneous insulin infusion (CSII) systems have been increasingly improved, leading to a high percentage of both adult and pediatric patients with diabetes now using insulin pumps. Different types of CSII systems are currently available, which are characterized by different settings and technical features. This longitudinal observational study aims to evaluate real-word glycemic outcomes in children and adolescents with type 1 diabetes using three different CSII devices: hybrid closed-loop (HCL) systems, predictive low glucose (PLGS) systems, and non-automated insulin pumps. The secondary objective was to identify clinical variables that may significantly influence the achievement of therapeutic goals in our study cohort. One-hundred-and-one patients on CSII therapy attending our pediatric diabetes center were enrolled. When compared with the non-automated group, patients using HCL systems showed higher levels of time in target glucose range (p = 0.003) and lower glucose variability (p = 0.008). Similarly, we found significantly better glucose metrics in HCL users in comparison to PLGS patients (time in range p = 0.008; coefficient of variation p = 0.009; time above 250 mg/dL p = 0.007). Multiple linear regression models showed that HCL systems (time in range p < 0.001) and high daily percentage of glycemic sensor use (time in range p = 0.031) are predictors for good glycemic control. The introduction and increasing availability of novel technologies for diabetes represent a promising strategy to improve glycemic control and quality of life in pediatric patients with type 1 diabetes. Our real-world data confirm the superiority of HCL systems in terms of improvement of time spent in the target glucose range, prevention of hypoglycemia, and reduction of glycemic variability
Cohort · Diabetes mellitus · Glycemic · Insulin · Insulin pump · Intensive care medicine · Observational study · Type 1 diabetes · Type 2 diabetes · Diabetes and associated disorders · Diabetes Management and Research · Medicine · Pancreatic function and diabetes · Endocrinology · Internal Medicine
| Citation velocity | historical |
|---|---|
| Highly cited | No |